Categories
Marijuana

An Investor Shows Interest in Kali Inc (OTCMKTS:KALY) ‘s Cannabis Extract Biopharmaceutical Technology: Kali Confirms Acquisition Interest

Kali Inc (OTCMKTS:KALY) doing business as kali Extracts has confirmed an investor’s acquisition interest in its Cannabis Extract Biopharmaceutical Technology. Chief Executive Officer of Kali, Frederick Ferri, said interest in its Cannabis Extract Biopharmaceutical Technology from an investor shows that its technology is undervalued. The company would release an update on acquisition interest on October 30, 2019.

Kali takes over NCMB in Q4 2018

Kali has taken over NCMB, which operates the patented cannabis extraction process in Q4 2018. Before acquired by Kali, NCMB is a leading player in developing plant-derived cannabinoid therapeutics with the help of the patented development process in its four years of operation. The manufacturing expertise, the established regulatory framework, and an intellectual property portfolio are the result of NCMB’s four-year operation.

Market for COPD

The market for chronic obstructive pulmonary disease (COPD) would touch $14 billion by the year 2025. Demand for Type 2 diabetes treatment is expected to reach $64 billion by the year 2026. The market for overall pain management is forecasted to reach $83 billion by the year 2024. Kali would supply CBD products for the treatment of these diseases.

Kali has filed a patent for a new formulation for the treatment of COPD symptoms. The company also applied for the trademark ‘RespRx,’ a brand name for the CBD formulation to treat COPD symptoms and other respiratory conditions. Kali is at an advantage with its new formulations for COPD cure.

To comply with US FDA requirements, Kali is in the process of getting its proprietary extracts, which are derived from the US-patented extraction process, certified. Kali has established substantial achievements since the update of the biopharmaceuticals strategy. The company associated with a major university to test and evaluate COPD treatment formulations. It will soon kickoff this evaluation process and issues an update at a later date. Advances made in the treatments helped Kali to establish new partnerships. The company would issue an update on new partnerships.

Puration Inc has obtained a limited license for the patented process of Kali to infuse cannabis extracts in its beverages. Kali is also marketing CBD infused candies under its brand name – Hemp4mula.

By Steven Russell

Steve covers business and investing in emerging medical marijuana markets. Steve graduated from the university of New Orleans with a degree in Broadcast Journalism. Steve has published several articles in professional journals and magazines. His experience gives readers an inside look at the intersection of his specialties, business and medical marijuana.

Leave a Reply

Your email address will not be published. Required fields are marked *

Pin It on Pinterest